Literature DB >> 6793694

Effects of L-deprenyl on human growth hormone secretion.

M Koulu, R Lammintausta.   

Abstract

The effects of L-deprenyl on L-dopa-, apomorphine- and L-tryptophan-induced growth hormone (GH) secretion were studied in thirteen healthy male volunteers. An acute 10 mg dose of L-deprenyl did not stimulate the basal GH secretion. Short-term L-deprenyl premedication significantly enhanced the L-dopa-stimulated GH release. In contrast, L-deprenyl premedication did not change the GH response to apomorphine or L-tryptophan. Potentiation of L-dopa-induced GH release by L-deprenyl indicates an increased availability of dopamine at the receptor level without a direct agonistic effect by the drug. Furthermore, L-deprenyl does not change the function of postsynaptic dopamine receptors involved in human GH release.

Entities:  

Mesh:

Substances:

Year:  1981        PMID: 6793694     DOI: 10.1007/BF01248954

Source DB:  PubMed          Journal:  J Neural Transm            Impact factor:   3.575


  25 in total

1.  Slight effect of L-tryptophan on growth hormone release in normal human subjects.

Authors:  E E Müller; F Brambilla; F Cavagnini; M Peracchi; A Panerai
Journal:  J Clin Endocrinol Metab       Date:  1974-07       Impact factor: 5.958

2.  Amantadine enhancement of L-DOPA induced growth hormone stimulation.

Authors:  F Massara; F Camanni; G M Molinatti
Journal:  Horm Metab Res       Date:  1973-11       Impact factor: 2.936

Review 3.  Monoamine oxidase inhibitors as anti-depressant drugs and as adjunct to L-dopa therapy of Parkinson's disease.

Authors:  M B Youdim
Journal:  J Neural Transm Suppl       Date:  1980

4.  Dopamine is a monoamine oxidase B substrate in man.

Authors:  V Glover; M Sandler; F Owen; G J Riley
Journal:  Nature       Date:  1977-01-06       Impact factor: 49.962

5.  L-deprenyl treatment of on-off phenomena in Parkinson's disease.

Authors:  U K Rinne; T Siirtola; V Sonninen
Journal:  J Neural Transm       Date:  1978       Impact factor: 3.575

6.  L-tryptophan and neuroendocrine regulation in neurologic patients: hormone responses to L-tryptophan loading in patients with hypothalamic lesions.

Authors:  M T Hyyppä; T Jolma; V A Långvik; O Kytömäki; E Syvälahti
Journal:  Psychoneuroendocrinology       Date:  1977-10       Impact factor: 4.905

7.  Changes in plasma growth hormone levels in normal and acromegalic subjects following administration of 2-bromo-alpha-ergocryptine.

Authors:  F Camanni; F Massara; L Belforte; G M Molinatti
Journal:  J Clin Endocrinol Metab       Date:  1975-03       Impact factor: 5.958

8.  Implications of combined treatment with 'Madopar' and L-deprenil in Parkinson's disease. A long-term study.

Authors:  W Birkmayer; P Riederer; L Ambrozi; M B Youdim
Journal:  Lancet       Date:  1977-02-26       Impact factor: 79.321

9.  Deprenyl in Parkinson's disease.

Authors:  A J Lees; K M Shaw; L J Kohout; G M Stern; J D Elsworth; M Sandler; M B Youdim
Journal:  Lancet       Date:  1977-10-15       Impact factor: 79.321

10.  Dopamine oxidation and its inhibition by (-)-deprenyl in man.

Authors:  V Glover; J D Elsworth; M Sandler
Journal:  J Neural Transm Suppl       Date:  1980
View more
  2 in total

1.  COMT inhibition by entacapone does not affect growth hormone or prolactin secretion in healthy volunteers.

Authors:  T Keränen; A Gordin; M Koulu; M Scheinin; S Antila; S Sundberg; T Wikberg
Journal:  J Neural Transm (Vienna)       Date:  1996       Impact factor: 3.575

2.  The functional consequences of inhibition of monoamine oxidase type B: comparison of the pharmacological properties of L-deprenyl and MDL 72145.

Authors:  J R Fozard; M Zreika; M Robin; M G Palfreyman
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  1985-11       Impact factor: 3.000

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.